Please use this identifier to cite or link to this item:
Title: Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion.
Austin Authors: King, Tracy;Jagger, Jacqueline;Wood, Jodie;Woodrow, Carmel;Snowden, Alicia;Haines, Sally;Crosbie, Christina;Houdyk, Kristen
Affiliation: Institute of Haematology, Royal Prince Alfred Hospital, Sydney, Australia
Cancer Services, Gosford Hospital, Gosford, NSW, Australia
Cancer Services, Flinders Medical Centre, Adelaide, SA, Australia
Division of Cancer Services, Princess Alexandra Hospital, Brisbane, QLD, Australia
Precision Haematology, Melbourne, Australia
Haematology and Stem Cell Transplantation Service, The Alfred Hospital, Melbourne, Australia
Haematology, St. Charles Gairdner Hospital, Nedlands WA, Australia
Cancer Clinical Trials Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: Jul-2018
Publication information: Asia-Pacific journal of oncology nursing 2018; 5(3): 270-284
Abstract: Patients with multiple myeloma (MM) are typically of an advanced age and may have significant co-existing medical conditions. They have often had multiple lines of therapy and as such experience disease-related effects alongside associated treatment toxicities. Daratumumab is a monoclonal antibody approved for the treatment of MM in the relapsed/refractory setting. Clinical studies found that daratumumab showed good tolerability as a monotherapy and in combination with current standard therapies. However, the administration of daratumumab does require specific management considerations. It is administered as an intravenous infusion and infusion-related reactions (IRRs) may occur. Daratumumab also interferes with routine blood transfusion tests, giving false positives for the indirect antiglobulin test. This article highlights key nursing care considerations and practical management aspects to improve the treatment experience of patients receiving daratumumab infusions. Pretreatment aspects, patient education, pre- and post-medication, daratumumab administration, and the management of IRRs are discussed. An IRR management sheet that could be used by nurses and a patient information sheet are located at the end of this article.
DOI: 10.4103/apjon.apjon_9_18
Journal: Asia-Pacific journal of oncology nursing
PubMed URL: 29963589
ISSN: 2347-5625
Type: Journal Article
Subjects: Daratumumab
infusion-related reaction
multiple myeloma
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 26, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.